SCHEMBL11070341

SCHEMBL11070341

CCOC(=O)c1cc2cnccc2s1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 7/20 0.53
DBF4 Q9UBU7 7/20 0.53
MAPK14 Q16539 1/20 0.48
HDAC3 O15379 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC2 Q92769 1/20 0.47
NCOR2 Q9Y618 1/20 0.47
GSK3B P49841 2/20 0.46
RPS6KA3 P51812 2/20 0.46
CHEK1 O14757 1/20 0.46
AURKA O14965 1/20 0.46
DAPK3 O43293 1/20 0.46
PRKD3 O94806 1/20 0.46
MAP4K4 O95819 1/20 0.46
PAK4 O96013 1/20 0.46
ABL1 P00519 1/20 0.46
RET P07949 1/20 0.46
PIM1 P11309 1/20 0.46
FGFR1 P11362 1/20 0.46
PRKACA P17612 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29374201 0.89 GSK3B (0.60) CDC7DBF4MAPK14GSK3BRPS6KA3
SCHEMBL842776 0.89 GSK3B (0.60) CDC7DBF4MAPK14GSK3BRPS6KA3
SCHEMBL160500 0.84 CDK8 (0.49) HDAC3HDAC1HDAC2NCOR2GSK3B
SCHEMBL2010041 0.81 HDAC1 (0.49) HDAC3HDAC1HDAC2NCOR2GSK3B
SCHEMBL21129497 0.80 HDAC1 (0.41) CDC7DBF4HDAC3HDAC1HDAC2
SCHEMBL3498715 0.80 MMP2 (0.59) CDC7DBF4MAPK14HDAC3HDAC1
SCHEMBL4405770 0.79 BCL2L1 (0.57) HDAC3HDAC1HDAC2DYRK1APTPN2
SCHEMBL29913871 0.79 BCL2L1 (0.57) HDAC3HDAC1HDAC2DYRK1APTPN2
SCHEMBL2009820 0.79 DYRK1A (0.56) MAPK14HDAC3HDAC1HDAC2NCOR2
SCHEMBL2238245 0.78 PTPN2 (0.60) CDC7DBF4HDAC3HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116730995-B Hydrazide compound, preparation method and application thereof 深圳微芯生物科技股份有限公司 2024-06-25 CN disclosed
EP-3480193-B1 PYRAZOLE DERIVATIVES AS ALK5 INHIBITORS AND USES THEREOF HANMI PHARMACEUTICAL CO LTD (KR) 2024-05-29 EP disclosed
US-10954232-B2 Pyrazole derivative as ALK5 inhibitor and uses thereof HANMI PHARMACEUTICAL CO., LTD. (KR) 2021-03-23 US disclosed
US-10954232-B2 Pyrazole derivative as ALK5 inhibitor and uses thereof HANMI PHARMACEUTICAL CO., LTD. (KR) 2021-03-23 US disclosed
US-20190194198-A1 NOVEL PYRAZOLE DERIVATIVE AS ALK5 INHIBITOR AND USES THEREOF HANMI PHARMACEUTICAL CO., LTD. (KR) 2019-06-27 US disclosed
US-20190194198-A1 NOVEL PYRAZOLE DERIVATIVE AS ALK5 INHIBITOR AND USES THEREOF HANMI PHARMACEUTICAL CO., LTD. (KR) 2019-06-27 US disclosed
EP-3480193-A1 NOVEL PYRAZOLE DERIVATIVE AS ALK5 INHIBITOR AND USES THEREOF Hanmi Pharmaceutical Co., Ltd. (KR) 2019-05-08 EP disclosed
US-4480098-A Preparation of alkali metal thieno(furo)pyridines ELI LILLY AND COMPANY (US) 1984-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190194198-A1 NOVEL PYRAZOLE DERIVATIVE AS ALK5 INHIBITOR AND USES THEREOF ALK, SMAD3, TGFBR1 CDC7 1263/4885DBF4 2626/4885MAPK14 190/4885
US-10954232-B2 Pyrazole derivative as ALK5 inhibitor and uses thereof ALK, SMAD3, TGFBR1 CDC7 1239/4885DBF4 2895/4885MAPK14 216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.